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Abstract
A lipopolysaccharide from Pantoea agglomerans (LPSpa) has been applied to various fields
for human use as a Toll-like receptor 4 ligand and its safety has been confirmed. Here, we
showed for the first time the application of LPSpa as an effective mucosal adjuvant for acti-
vating vaccine-induced antigen specific immune responses. Mice sublingually immunized
with influenza vaccine (HA split vaccine) with LPSpa induced both HA-specific IgG (system-
ic) and IgA (mucosal) antibody responses, which led to a significant increase in survival rate
against lethal influenza virus challenge compared with subcutaneous vaccination. After
sublingual administration of ovalbumin with LPSpa, ovalbumin-specific mucosal IgA re-
sponses were induced at both mucosal surfaces close to the immunized site and at remote
mucosal surfaces. Sublingual administration of LPSpa evoked local antigen-uptake by den-
dritic cells in cervical lymph nodes. LPSpa induced cytokine production and the maturation
and proliferation of innate immune cells via Toll-like receptor 4 in dendritic cells. Collectively,
these results suggest that LPSpa can be used as an effective mucosal adjuvant to stimulate
and activate local innate immune cells to improve and enhance mucosal vaccine potency
against various pathogens.
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Introduction
Almost all environmental pathogens enter the body through mucosal surfaces including the re-
spiratory, gastrointestinal, and genital tracts that act as the first line of defense. Therefore, muco-
sal vaccination is one of the most effective prophylaxes to prevent infectious diseases because it
elicits both mucosal and systemic immune responses [1–3]. The sublingual (s.l.) administration
of antigens has been well documented for allergen desensitization therapy [4, 5]. The s.l. route
has recently been demonstrated to be an attractive site for vaccination against various bacterial
and viral diseases [6–10] because antigens are not exposed to degradation caused by gastrointes-
tinal tract [11] and are prevented from being redirected to the central nervous system [12–14].
For inactivated antigens, sufficient immune responses that protect from infectious patho-
gens, especially at mucosal surfaces, can be enhanced by co-administration with adjuvants
(immunostimulation). S.l. administration of inactivated influenza vaccine (A/PR/8) with a sub-
unit of mutant cholera toxin (CT) and B subunit of a heat-labile toxin (LT) (mCTA/LT) in-
duced humoral immune responses and protected against influenza virus infection [13], these
enterotoxins, CT and LT, are able to act as adjuvants [15–17]. Local IgA responses and salivary
hemagglutination inhibition (HI) responses were elicited by s.l. vaccination of influenza H5N1
virosomes in combination with a bacterial second messenger, c-di-GMP [18]. Moreover, some
Toll-like receptor (TLR) ligands are potential mucosal adjuvants for HIV gp140 and tetanus
toxoid [19]. These findings suggest that vaccination by the s.l. route with a suitable adjuvant is
an attractive method for the administration of vaccines. However, because of safety concerns,
few adjuvants such as alum and monophosphoryl lipid A (MPL), have been used in humans.
To develop safer adjuvants, especially for s.l. vaccination, we have focused on substances al-
ready approved for human use.
LPSpa is a lipopolysaccharide (LPS) (TLR4 ligand) derived from Pantoea agglomerans, a
Gram-negative bacterium that grows symbiotically with wheat [20, 21]. The oral or intrader-
mal administration of this substance, a water extract of flour or purified from Pantoea agglom-
erans, evokes innate immune cells like macrophages to prevent and treat various health
disorders including pathogenic infection, type I allergic reactions and cancer [22–26]. More-
over, safety trials of the fermented flour extracts containing LPSpa as an active ingredient using
reverse mutation or chromosome aberration tests, single-dose toxicity, repeated dose toxicity
and other skin safety studies were performed [27]. These studies confirmed that oral and trans-
dermal administration of LPSpa derived from fermented flour extract showed no significant
toxicity at doses that evoked immune responses. Based on these features, several products were
launched; for example, an application in health food to prevent and improve metabolic syn-
dromes, skincare products to maintain the healthy state of skin and foodstuffs for stockbreed-
ing and aquatic culture to activate innate immunity.
In this study, we evaluated the mucosal adjuvant activities of s.l. administered LPSpa in the
induction of antigen-specific humoral immune responses. S.l. administration of antigens with
LPSpa efficiently induced both systemic IgG and mucosal IgA production by activating innate
immune cells: maturation of dendritic cells (DCs), the release of pro-inflammatory cytokines
and antigen-migration. Our findings suggest that LPSpa is a potential adjuvant for the en-
hancement of s.l. vaccines.
Materials and Methods
Vaccine, adjuvant and reagents
Influenza HA split vaccines derived from A/California/07/2009 (H1N1) pdm09, A/Victoria/
361/2011 (H3N2), B/Wisconsin/1/2010 and A/Puerto Rico/8/34 (H1N1) (PR8) were kindly
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provided from The Research Foundation for Microbial Diseases of Osaka University, Japan.
PR8 viruses were prepared as previously described [28]. Ovalbumin (OVA) was purchased
from Sigma Aldrich, USA. MPL was purchased from InvivoGen, USA. LPSpa was purchased
fromMacrophi Inc., Japan.
Mice
Female C57BL/6 and BALB/c mice (aged 6 to 8 weeks) were purchased from SLC, Japan. The
mice were reared at 23°C with a 12 h light/dark cycle and were allowed free access to standard
rodent chow and water. The mice were housed for at least 5 days to adapt to their environment
before experiments. All animal experiments were performed in accordance with the guidelines
of the Institutional Animal Care and Use Committee of Research Institute for Microbial Dis-
eases, Immunology Frontier Research Center of Osaka University and Nitto Denko Corpora-
tion, who specifically approved this study (Permit Number: C13H, C13I, C14E and C14F).
Especially, survival studies were reviewed and approved by the animal ethics committee of Im-
munology Frontier Research Center of Osaka University. All efforts were made to minimize
suffering under the guideline adherence.
Immunization and sample collection
Mice were immunized twice at weekly intervals under anesthesia with thiamylal and xylazine.
For s.l. vaccination, forceps were placed under the tongue, the mouth was opened wide and
30 μl of vaccine solution was administered by micropipette. Seven days after the last immuniza-
tion, serum and mucosal secretions (nasal washes, bronchial lavage fluids [BALF], vaginal
washes and fecal extracts) were collected. Nasal, bronchial lavage and vaginal mucosa were
washed with 200, 500 or 150 μl of phosphate buffered saline (PBS), respectively. Fecal pellets
were suspended in PBS (100 mg/ml) and extracted by vortexing for 10 min. After centrifuga-
tion at 3000 ×g for 10 min the supernatants were used as fecal extracts. For a longitudinal study
to assess the persistence of antigen-specific immune responses, at 1, 4, 8 and 12 weeks after the
last immunization, serum and nasal washes were collected.
Antigen-specific IgG and IgA enzyme-linked immunosorbent assay
The titers of antigen-specific antibodies in serum and mucosal samples were determined. Immu-
noplates were coated with influenza vaccine (H1N1, H3N2 or B at 2.5 μg/ml) or OVA at 100 μg/
ml in advance. After blocking with BlockAce (Dainippon Sumitomo Pharmaceutical, Japan),
two-fold serial dilutions of the samples were added to the immunoplate followed by the addition
of horseradish peroxidase-conjugated anti-mouse IgG or IgA (Bethyl Laboratories, USA). After
adding TMB peroxide substrate (Nacalai Tesque, Japan) and stop solution, end-point titers were
determined by the maximum dilution that exceeded 0.1 at an absorbance of 450 nm.
HI assay
Serum samples were treated with RDE II (Denka Seiken, Japan) at a final dilution of 1:10. Two-
fold serial dilutions of the samples were incubated with an equal volume containing 8 HA of
split vaccine (H1N1). Then, chicken red blood cells (0.5% [v/v]) were added and incubated. HI
titers were determined by the maximum dilution that showed non-agglutination.
Virus infection
Seven days after the last immunization, mice were intranasally infected with 15 μl of PR8 virus
(8.2×10−1 HA unit: 100×LD50) under anesthesia with thiamylal and xylazine. Survival rate of
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experimental mice is monitored daily, and their body weights were also measured every two
days. Mice with a weight loss of more than 30% of the starting body weight were considered as
dead and were humanely euthanized by cervical dislocation. At 5 days after virus challenge,
lungs of some mice were harvested and fixed with 4% formalin. Lung sections embedded in
paraffin wax were stained with hematoxylin-eosin (Wako, Japan).
Cells and stimulation
Peritoneal macrophages: at 3 days after intraperitoneal injection of 2 ml of 4% (w/v) thioglycol-
late medium (Sigma Aldrich, USA), the mice were sacrificed and peritoneal exudate cells were
isolated by washing with PBS. Bone-Marrow derived DCs (BMDCs): mice were sacrificed and
bone marrow cells were harvested from the femurs and tibias by flushing the marrow cavity
with PBS and then cultured with complete RPMI 1640 (supplemented with 10% fetal calf
serum [FCS], 50 mM 2-ME, 1% penicillin [100 U/ml], 1% streptomycin [100 U/ml]) and 10
ng/ml mouse granulocyte-macrophage colony-stimulating factor (GM-CSF, PeproTech, USA)
for 6 days as previously described [29]. Cells were collected and 1×106 cells/ml were stimulated
with LPSpa or MPL for the indicated times and concentrations. To assess the functional role of
TLR2 and TLR4, peritoneal macrophages were incubated with 1 μg/ml of anti-TLR2 monoclo-
nal antibody (mAb), anti-TLR4 mAb or isotype control Ab (all Abs were purchased from Bio-
Legend, USA) for 30 min before stimulation.
Cytokine enzyme-linked immunosorbent assay
Cell culture supernatants were assessed for concentrations of interleukin (IL)-6 and tumor ne-
crosis factor (TNF)α by enzyme-linked immunosorbent assay (ELISA) according to manufac-
turer’s instructions (R&D Systems, USA).
Flow cytometry
FITC-CD11c antibodies were purchased from BD Pharmingen, USA and APC-CD40, CD80
and CD86 were purchased from BioLegend. Cells were washed in flow-cytometry buffer (2%
[v/v] FCS and 2 mM EDTA in PBS, pH 7.5), then incubated with each antibody for 20 min and
washed twice with flow-cytometry buffer. The cells were analyzed by flow cytometry on a
FACSCalibur instrument (BD Biosciences, USA), followed by data analysis using FlowJo v7.6.5
software (Tree Star).
In vivo Ag migration assay
Alexa 647 OVA (50 μg) (Molecular Probes, USA) with or without LPSpa (5 μg) was adminis-
tered sublingually under anesthesia with thiamylal and xylazine. After 18 h, cervical lymph
nodes were harvested and single cell suspensions were stained with FITC-CD11c and assessed
by flow cytometry.
Proliferation assay
BMDCs were collected and stimulated with LPSpa (10 ng/ml) for 8 h. Cells were stained with
propidium iodide (PI) buffer (0.4% sodium citrate, 0.03% Nonidet P-40, 0.05 mg/ml PI
[Sigma] and 0.02 mg/ml RNase A) and assessed by flow cytometry.
Statistics
All error bars indicate standard deviation (SD). Two-tailed student t-test was used to compare
significant differences between two groups, whereas one-way ANOVA with Dunnett’s or
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Tukey’s test was used to compare differences among three or more groups. For survival curves,
groups were compared with a log-rank test.
Results
LPSpa is a potent adjuvant and induces HA-specific humoral responses
by s.l. immunization
To clarify whether LPSpa activates immune responses as a mucosal adjuvant for s.l. vaccina-
tion against seasonal influenza viruses, we utilized HA split vaccines containing 3 strains,
H1N1, H3N2 and B. These vaccine strains were selected for the 2012/13 season in Japan
(IASR from National Institute of Infectious Diseases). The efficacy of such adjuvant-less split
vaccines via injection was low especially for young children [30, 31]. The levels of H1N1,
H3N2 and B strain specific serum IgG and mucosal IgA were determined by ELISA (Fig 1A–
1D) or HI assay (Fig 1E). As shown in Fig 1A, serum HA specific IgG responses against each
Fig 1. Seasonal influenza split s.l. vaccination with LPSpa induced HA-specific immune responses in serum andmucosa. BALB/c mice were divided
into 4 groups and immunized twice s.c. or s.l. with H1N1, H3N2 and B strain-derived split vaccine (0.1 μg) with or without LPSpa (1 μg) at weekly intervals
(n = 4–7). The titers of HA-specific (A) serum IgG and (B) nasal IgA were assessed by ELISA. In s.c. and s.l. with LPSa groups, at 1, 4, 8 and 12 weeks after
the last immunization, HA (H1N1)–specific (C) serum IgG and (D) nasal IgA were assessed by ELISA (n = 4–5). (E) HI titers in 3 groups were measured in
serum by HI assay (n = 5). Results were representative of at least three experiments. ***P<0.001, by one-way ANOVA with Tukey’s test (H1, H3 and B were
assessed independently [A, B]). N.S., not significant. N.D., not detectable.
doi:10.1371/journal.pone.0126849.g001
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strain were increased in s.l. immunized mice and especially, mice immunized s.l. with vac-
cines containing LPSpa induced HA-specific IgG, whose levels were comparable to s.c. immu-
nization with vaccines. The HI assay showed the same tendency as ELISA, where both s.c.
and s.l. immunization with LPSpa induced sufficient production of HI Abs (H1N1) in serum
(Fig 1E). In contrast, HA-specific IgA was not detected in the nasal wash after s.c. immuniza-
tion compared with the non-treatment group, but mucosal vaccination induced IgA re-
sponses (Fig 1B). Moreover, s.l. immunization with LPSpa significantly enhanced HA-
specific IgA responses compared with s.l. immunization without LPSpa (Fig 1B). Additional-
ly, high levels of long lasting HA-specific Abs (H1N1) were observed until 12 weeks after the
final immunization (Fig 1C and 1D). These results demonstrate that s.l. immunization with
LPSpa elicited both systemic IgG comparable to s.c. immunization and mucosal IgA re-
sponses, which were not induced by s.c. immunization.
Fig 2. S.l. vaccination of PR8 split vaccine with LPSpa protectedmice from viral challenge. BALB/c mice were divided into 3 groups and immunized
twice s.c. with 0.1 μg PR8 vaccine or s.l. with PR8 vaccine (0.1 μg) and 5 μg LPSpa at weekly intervals. The titer of PR8-specific (A) serum IgG and (B) nasal
IgA were assessed by ELISA (n = 4). Seven days after the last immunization, mice were challenged with a lethal dose (100×LD50) of PR8 virus and (C)
survival rates were recorded (n = 8–10). (D) Lung sections at 5 days after virus challenge were stained with hematoxylin-eosin to evaluate cellular infiltration
(n = 3). Similar experiments were performed at least three times and one representative experiment is shown. ***P<0.001, by the log-rank test. N.D.,
not detectable.
doi:10.1371/journal.pone.0126849.g002
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S.l. vaccination of PR8-split vaccine with LPSpa protects mice against
lethal challenge with influenza virus
Next, we utilized split vaccine and viruses derived from the PR8 (H1N1) strain commonly used
as a laboratory mouse-adapted influenza strain, to determine whether s.l. immunization pro-
vided protective immunity against lethal virus challenge. As seen in Fig 2A and 2B, sufficient
production of PR8-specific IgG in serum was comparable between s.l. and s.c. vaccination
groups but PR8-specific IgA in nasal wash was only induced efficiently by the s.l. route. Seven
days after the last immunization, mice were infected intranasally with 100×LD50 of PR8 virus
and monitored daily. As shown in Fig 2C, all non-treated mice (10/10) died within 10 days
after virus infection (eight of them died by viral infection without euthanasia and 2 of them
with a weight loss of more than 30% at day 8 were euthanized and recorded as dead). However,
about 60% (5/8) of mice immunized s.c. survived, although transient body-weight loss was ob-
served (data not shown). Moreover, about 90% (8/9) of mice immunized s.l. survived without
any body-weight loss (data not shown). Three out of 8 and 1 out of 9 mice with vaccination
groups were dead by viral infection without euthanasia. On day 5 after virus challenge, histo-
logical analysis showed that lung sections from non-treated mice and mice immunized subcu-
taneously exhibited severe damage caused by massive lymphocyte infiltration and
inflammatory hyperemia. In contrast, lung sections from mice immunized sublingually did not
induce significant lung pathology (Fig 2D). These results indicate that s.l. vaccination with
LPSpa enhanced significant protective responses against lethal virus challenge due to both sys-
temic and especially mucosal PR8 specific Ab production.
S.l. vaccination of OVA with LPSpa induces OVA-specific immune
responses at remote mucosal surfaces
This study demonstrated the efficient immunization of influenza vaccine with LPSpa via oral
mucosa. Because mucosal vaccination induced antigen specific IgA responses at the immu-
nized site and at remote mucosal surfaces [32], we utilized OVA, a commonly used model anti-
gen for vaccination, and assessed the production of OVA-specific IgA at various mucosal areas
after s.l. immunization with LPSpa. As shown in Fig 3A, levels of OVA-specific IgG in serum
were significantly higher when immunization contained LPSpa. Additionally, OVA-specific
IgA in nasal washes as well as BALF, fecal extracts and vaginal washes were significantly in-
duced after s.l. vaccination with LPSpa (Fig 3B–3E). These results suggest that s.l. vaccination
with LPSpa elicited both systemic IgG and mucosal IgA responses in the trachea, intestine and
genital tract, indicating its potential application for vaccines to defend against various patho-
gens such as norovirus, human immunodeficiency virus and human papilloma virus.
S.l. administration of LPSpa activates DCmigration at early stage
After vaccination, the innate immune system is activated and DCs that function as antigen pre-
senting cells capture antigens and migrate to adjacent local lymph nodes where they present anti-
gens to T cells followed by the activation of the adaptive immune system [30]. To examine
whether LPSpa elicited antigen uptake and migration of DCs, we administered Alexa 647-conju-
gated OVA (50 μg) with or without LPSpa (5 μg) and the proportion of OVA containing CD11c+
DCs in cervical lymph nodes was determined after 18 h. As shown in Fig 4, the number of OVA
containing DCs increased in the presence of LPSpa. However, there were few OVA containing
DCs in mediastinal lymph node in all groups (data not shown). These results indicate that s.l. vac-
cination with LPSpa can enhance the efficacy of antigen uptake and migration of DCs to cervical
lymph nodes via the s.l. route leading to a link between innate and adaptive immunity.
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Innate immune cells produce cytokines, proliferate and mature after
stimulation with LPSpa via TLR4
LPSpa is a TLR4 ligand and signaling pathways triggered by TLRs lead to the production of
proinflammatory cytokines, such as IL-6, IL-12p40, TNF, and type I interferons (IFNs) [33].
Additionally, signaling pathways increase the surface expression of costimulatory molecules,
such as CD40, CD80 and CD86 on DCs, which are hallmarks of cellular activation [34]. Re-
sponses of peritoneal macrophages were measured after stimulation with LPSpa and MPL, an-
other TLR4 ligand approved as an adjuvant for human vaccination, as a control. As shown in
Fig 5A and 5B, the levels of IL-6 and TNF production in response to LPSpa or MPL for 24 h
Fig 3. Induction of OVA-specific IgG and IgA in serum or various mucosal areas by LPSpa. BALB/c mice, divided into 3 groups, were s.l. immunized
with 10 μg OVA or a mixture of OVA (10 μg) and 1 μg LPSpa twice at weekly intervals (n = 4). Seven days after the last immunization, samples were collected
and the titers of (A) serum IgG, (B) nasal IgA, (C) BALF IgA, (D) fecal IgA and (E) vaginal IgA were assessed by ELISA. Results are representative of three
independent experiments. *P<0.05, ***P<0.001, by one-way ANOVA with Tukey’s test. N.D., not detectable.
doi:10.1371/journal.pone.0126849.g003
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were increased dose-dependently, and the production of cytokines in response to LPSpa was
significantly higher than for MPL at an equal concentrations. To investigate the contribution
of TLR4 in cytokine production in response to LPSpa, peritoneal macrophages were treated
with isotype control Ab, TLR2 mAb or TLR4 mAb followed by stimulation with LPSpa. The
production of IL-6 in response to stimulation with LPSpa (1 ng/ml) was severely impaired by
TLR4 mAb pretreatment (Fig 5C), indicating TLR4 signaling is critical for the production of
cytokines in response to LPSpa.
Next, we generated BMDCs by cultivating bone marrow cells in the presence of GM-CSF.
As shown in Fig 6A and 6B, the production of IL-6 and TNF in response to stimulation with
LPSpa was also increased similar to that in peritoneal macrophages. The number of cells ex-
pressing CD40, CD80 and CD86 was increased after stimulation with LPSpa in a dose-depen-
dent manner (Fig 6D). Additionally, BMDCs proliferated about 1.5-fold faster than in the non-
treatment group in the presence of LPSpa (0.1–1000 ng/ml) (Fig 6C). The contribution of
LPSpa to cell-cycle progression in BMDCs was examined and BMDCs in S and G2/M phases
were increased after stimulation with LPSpa for 8 h (Fig 6E). Taken together, these findings
demonstrate that LPSpa can evoke innate immune cells such as macrophages and DCs fol-
lowed by the production of proinflammatory cytokines, up-regulation of costimulatory mole-
cules and proliferation via the TLR4 signaling pathway.
Discussion
In this study, we discovered a novel function of LPSpa as an adjuvant that induces humoral im-
munity, including systemic IgG and mucosal IgA responses, after s.l. vaccination, by activating
innate immune cells via TLR4.
It has been shown that s.l. administration is potentially safer than intranasal administration
[13, 14]. Antigens and/or adjuvants administered intranasally can be redirected to the central
nervous system through the olfactory bulbs and brain. For example, a clinical trial of intranasal
vaccination of antigens and LT in Switzerland showed some cases of Bell’s palsy, and CT was
reported to redirect antigens into olfactory tissues in mice [14, 35]. Such safety concerns might
limit the usefulness of intranasal vaccines in humans. In contrast, after s.l. administration, vac-
cine components such as inactivated vaccine and live virus were not transported into olfactory
bulbs and brain [13]. Therefore, mucosal priming and action mechanisms would be different
between the intranasal and s.l. routes because antigen-loaded antigen presenting cells were
Fig 4. Enhanced Ag uptake of DCs in cervical lymph nodes in the presence of LPSpa. BALB/c mice, divided into 3 groups, were s.l. administered with
50 μg Alexa 647 OVA with or without LPSpa (5 μg) (n = 3). After 18 h, cervical lymph nodes were removed and cells were assessed by flow cytometry.
Results are representative of three or more independent experiments. *P<0.05, by one-way ANOVA with Tukey’s test. N.D., not detectable.
doi:10.1371/journal.pone.0126849.g004
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observed mainly in mediastinal lymph nodes after intranasal administration [36], and in cervi-
cal lymph nodes after s.l. administration.
TLRs, one of the best-characterized pattern recognition receptors, are transmembrane pro-
teins that recognize microbial components on the cell surface or in endosomes followed by the
activation of innate immune cells such as macrophages and DCs [37]. On the basis of these fea-
tures, many TLR ligands have been used as vaccine adjuvants. Intranasal administration of in-
fluenza vaccine with Poly(I:C) (TLR3 ligand) and/or zymosan (TLR2 ligand) induce antigen-
specific IgG and IgA responses [38]. CpG ODN (TLR9 ligand) is a potent adjuvant for influen-
za vaccine by s.c. administration [39]. Transdermal administration of imiquimod (TLR7 li-
gand) enhanced both humoral and cellular immunity [40, 41]. Thus, various TLR ligands have
been investigated for potential use as adjuvants, and whose effectiveness likely depends on the
tissue distribution of TLRs. TLR4 is highly expressed in oral mucosal regions (vestibular/buccal
region and sublingual region) and soluble forms of TLR4 and CD14 are present in human sali-
va and interact with oral commensal and pathogenic bacteria [42, 43]. These reports suggest
that s.l. vaccination with TLR4 ligand might be an ideal vaccination strategy.
Fig 5. Cytokine production frommousemacrophages after stimulation with LPSpa via TLR4. Thioglycollate-elicited peritoneal macrophages were
collected from BALB/c mice. Cells were stimulated for 24 h with MPL (0.1, 1, 10, 100, 1000 ng/ml) or LPSpa (0.1, 1, 10, 100, 1000 ng/ml) and (A) IL-6 or (B)
TNF levels in supernatants were measured by ELISA (n = 3). Macrophages were treated with isotype Ab, TLR2mAb or TLR4mAb for 2 h before stimulation
with LPSpa (1 ng/ml) and 24 h later, (C) IL-6 production of supernatants was measured by ELISA (n = 3). Results are representative of two (C) or three (A, B)
independent experiments. *P<0.05, **P<0.01, ***P<0.001, by Two-tailed student t-test when comparing between two groups and one-way ANOVA with
Tukey’s test when comparing between three groups.
doi:10.1371/journal.pone.0126849.g005
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We found that LPSpa induced greater amounts of cytokines than MPL after stimulation of
macrophages and DCs. MPL from Salmonella minnesota was used in this study as a control for
TLR4 ligand. MPL has already been approved as an adjuvant in combination with AS04
(alum), in Cervarix and Fendrix produced by GlaxoSmithKline Biologicals for human papillo-
ma virus and hepatitis B virus, respectively. However, in a previous study, s.l. immunization of
HIV-1 CN54gp140 or tetanus toxoid with MPL did not induce strong antigen specific re-
sponses (IgG and IgA production) [19] probably because activation of innate immune cells by
MPL was not sufficient to evoke humoral immunity.
In this study, we demonstrated that antigen-specific IgA production was strongly induced
in the respiratory tract, intestine and vaginal tract after s.l. immunization with OVA and
LPSpa. Previous studies have found that s.l. vaccination induced the migration of antigen-spe-
cific IgA Ab-secreting cells into the vaginal mucosa in a CCL28-dependent manner and both
migratory CD8α- and resident CD8α+ DCs were responsible for efficient priming of antigen-
specific T and B cells in the cervical lymph nodes, regulated by CCL7-CCL19/CCL21 [8, 44]. It
Fig 6. Cytokine production, proliferation andmaturation of BMDCs after stimulation with LPSpa. BMDCs were obtained from C57BL/6 mice-derived
bone marrow cells cultured with GM-CSF. Cells were stimulated for 24 h with MPL (0.1, 1, 10, 100, 1000 ng/ml) or LPSpa (0.1, 1, 10, 100, 1000 ng/ml) and
(A) IL-6 or (B) TNF levels in supernatants were measured by ELISA (n = 3). (C) Total cell numbers were counted (n = 3) and (D) the maturation of BMDCs
was assessed by measuring the expression levels of CD40, CD80 and CD86 by flow cytometry (n = 3). (E) Cells were stimulated for 8 h with LPSpa (1000
ng/ml) and then stained with propidium iodide and analyzed by flow cytometry (n = 3). Results are representative of three (C, D), four (E) or five (A, B)
independent experiments. *P<0.05, **P<0.01, ***P<0.001, by Two-tailed student t-test when comparing between two groups and one-way ANOVA with
Dunnett’s test when comparing three or more groups.
doi:10.1371/journal.pone.0126849.g006
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has been demonstrated that antigen-loaded DCs from s.l. mucosa recirculate to distant lym-
phoid organs, such as genital nodes, to activate antigen-specific CD8+ T cells [45]. These find-
ings imply that LPSpa-based s.l. vaccines can be applied to protect against pathogen infection
via various mucosal routes.
For the prevention of influenza virus infection, there are three different types of vaccines:
live-attenuated virus vaccine, formalin-inactivated whole-virus vaccine and HA split vaccine
[31]. It has been shown that HA split vaccine, currently used for seasonal vaccination in Japan
to avoid adverse effects, contains only purified components (lacks virus-derived RNA [TLR7 li-
gand]) and does not induce innate immune responses due to the absence of TLR7/MyD88
pathway signaling [30, 31]. Therefore, after vaccination with the split vaccine, naïve mice that
had never experienced influenza virus infection could not sufficiently protect against virus
challenge [31]. This suggests that adjuvant activity via TLR ligands is essential for the efficient
induction of adaptive immunity. Additionally, secreted IgA in the respiratory tract protected
against virus infection and is important for cross-protection against heterologous influenza
virus strains [46]. In this study, we demonstrated that s.l. vaccination with split vaccine and
LPSpa induced efficient production of serum IgG and mucosal IgA at a relatively low vaccine
dose (0.1 μg). Thus, s.l. vaccination with LPSpa against influenza virus might be a useful
vaccination method.
In the survival study (Fig 2C), we determined 30% of body weight loss as a humane end-
point because 15%-35% of body weight loss and/or moribund conditions have been commonly
used as humane endpoints [47–51]. However, judging from the results, it may not have been
appropriate in terms of animal welfare because most of mice were dead by viral infection with-
out euthanasia. For future work, in an influenza (especially PR8 virus) challenge study, we
strongly recommend that mice which have weight loss of more than 25% of the body weight
and/or are in moribund conditions such as no eating, no drinking, marked immobility and dull
fur are considered to reach an experimental and a humane endpoint.
In summary, this study clearly demonstrated that LPSpa is an effective adjuvant for mucosal
vaccine that can elicit humoral immunity, both systemic and local immunoresponses, after s.l.
vaccination. Now we have been developing and improving LPSpa as a candidate adjuvant for
human use and non-clinical evaluation, all in vivo and in vitro studies, has been ongoing. In the
future, we would like to evaluate the efficacy of LPSpa-adjuvanted vaccines in pre-clinical mon-
key studies followed by the development of safer vaccines for humans.
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